Switch theme
Sign up to access all valuation multiples
NRGene Technologies Ltd is engaged in the development of artificial intelligence-based software for the analysis of genetic information in order to improve species of plants and animals.
n/a
Last FY Revenue $0.4M
Last FY EBITDA -$0.8M
$8.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, NRGene achieved revenue of $0.4M and an EBITDA of -$0.8M.
NRGene expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NRGene valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | XXX | 21% | XXX | XXX | XXX |
| EBITDA | XXX | -$0.8M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -209% | XXX | XXX | XXX |
| EBIT | XXX | -$1.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -346% | XXX | XXX | XXX |
| Net Profit | XXX | -$1.0M | XXX | XXX | XXX |
| Net Margin | XXX | -260% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, NRGene's stock price is ILS 2 (or $1).
NRGene has current market cap of ILS 31.9M (or $9.1M), and EV of ILS 28.0M (or $8.0M).
See NRGene trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.0M | $9.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, NRGene has market cap of $9.1M and EV of $8.0M.
NRGene's trades at 21.7x EV/Revenue multiple, and -10.4x EV/EBITDA.
Equity research analysts estimate NRGene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NRGene's P/E ratio is not available.
See valuation multiples for NRGene and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.1M | XXX | $9.1M | XXX | XXX | XXX |
| EV (current) | $8.0M | XXX | $8.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 21.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.4x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNRGene's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
NRGene's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NRGene's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NRGene and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -209% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 11% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 140% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 367% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Presight AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Pointerra | XXX | XXX | XXX | XXX | XXX | XXX |
| Beamtree | XXX | XXX | XXX | XXX | XXX | XXX |
| Unith | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NRGene acquired XXX companies to date.
Last acquisition by NRGene was XXXXXXXX, XXXXX XXXXX XXXXXX . NRGene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| Where is NRGene headquartered? | NRGene is headquartered in Israel. |
| Is NRGene publicy listed? | Yes, NRGene is a public company listed on TAE. |
| What is the stock symbol of NRGene? | NRGene trades under NRGN ticker. |
| When did NRGene go public? | NRGene went public in 2021. |
| Who are competitors of NRGene? | Similar companies to NRGene include e.g. Presight AI, Benevolent AI, Pointerra, Beamtree. |
| What is the current market cap of NRGene? | NRGene's current market cap is $9.1M |
| Is NRGene profitable? | Yes, NRGene is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
